SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

An initial misreport of Webull's earnings per share sparked controversy and accusations of manipulation, yet bulls highlight strong revenue growth and record customer assets against persistent concerns over dilution.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending after reporting strong earnings and providing robust forward guidance, projecting AI chip revenue to exceed $100 billion by 2027, driven by strategic commitments from major hyperscaler customers. The community is actively discussing the company's accelerating AI momentum and potential analyst upgrades, alongside comparisons to other AI stocks' recent post-earnings reactions.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending following a massive insider share purchase by CEO Jeff Green, signaling strong executive confidence. This, alongside widespread rumors of an OpenAI partnership for ad sales, is sparking community speculation about a potential short squeeze for the recently oversold stock.

Amprius Technologies, Inc. engages in the development, manufacture, and market lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the United States and Rest of the World geographical segments. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending following strong Q4 2025 earnings that surpassed revenue and adjusted earnings expectations, coupled with the announcement of a strategic U.S. manufacturing partnership. The community is highlighting the company's asset-light model and its critical role in the expanding drone and defense sectors due to its advanced battery technology.

Okta, Inc. engages in the provision of an identity management platform for enterprises. It operates through the United States and International geographical segments. The firm's products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta's Q4 earnings surpassed expectations, but weaker Q1 guidance has sparked a mixed market reaction; community discussion centers on whether Wall Street is overlooking the company's strong full-year outlook and its strategic positioning to secure human and emerging AI identities.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is trending due to heightened geopolitical tensions in the Middle East, with ongoing reports of attacks on oil infrastructure and disrupted tanker traffic in the Strait of Hormuz driving community discussion about significant oil supply impacts.

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals is seeing significant momentum driven by widespread buyout speculation, fueled by strong revenue growth for its lead oncology drug OJEMDA and recent strategic pipeline expansion into ADCs; the community is actively anticipating an acquisition in a red-hot biotech M&A market.

The Campbell's Co. engages in the business of manufacturing and marketing food and beverage products. It operates under the Meals and Beverages, and Snacks segments. The Meals and Beverages segment includes soup, meals, and beverage products in retail and foodservice. The Snacks segment offers cookies, crackers, bakery, and frozen products. The company was founded by Joseph Campbell and Abraham Anderson in 1869 and is headquartered in Camden, NJ.

Campbells Co (The)

Campbell Soup Co.

Campbell Soup Co. is trending as it touches multi-year lows following a sector-wide slump driven by General Mills' cautious outlook and ongoing analyst downgrades. However, community discussions are sharply divided, with some viewing it as a deeply undervalued defensive play with strong dividend appeal, anticipating significant upside from potential tariff relief and strategic brand performance despite concerns over debt and margin compression.

American Eagle Outfitters, Inc. is a multi-brand specialty retailer, which offers an assortment of apparel and accessories for men and women under the American Eagle Outfitters brand, and intimates, apparel and personal care products for women under the Aerie brand. The firm operates stores in the United States, Canada, Mexico, Hong Kong, China and the United Kingdom. It also acquired two emerging brands to complement its existing brands, Tailgate, a vintage sports-inspired apparel brand, and Todd Snyder New York, a premium menswear brand. The company was founded in 1977 and is headquartered in Pittsburgh, PA.

American Eagle Outfitters Inc.

American Eagle Outfitters, Inc.

American Eagle Outfitters is trending after reporting better-than-expected Q4 earnings, driven by strong comparable sales, particularly from its Aerie brand. However, community discussion is mixed, with many speculating that the announced dividend signals a long-term holding strategy rather than immediate aggressive growth, leading to after-hours selling pressure despite the positive results.

Veeva Systems, Inc. engages in the provision of industry cloud solutions for the global life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm's customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage regulated, content-centric processes across the enterprise. The company's customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007, and is headquartered in Pleasanton, CA.

Veeva Systems Inc - Ordinary Shares - Class A

Veeva Systems is trending after reporting strong Q4 earnings and providing robust FY27 guidance, leading to a significant surge in trading volume and largely bullish community sentiment. Investors are actively discussing the company's AI initiatives as a key driver for future growth and efficiency within the life sciences sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company's Q4 adjusted loss was $0.48 per share, while revenue of $17.5 million beat expectations of $16.84 million.</li><li>Avmapki Fakzynja co-pack generated $17.5 million in Q4 revenue and $30.9 million in 2025 following FDA approval in May.</li><li>The KRAS cancer drug VS-7375 cleared multiple dose levels with no safety issues.</li></ul>Shares of Verastem, Inc. (VSTM) rose nearly 3% in after-hours trading on Wednesday, even after the cancer drug developer reported a quarterly earnings miss, as investors focused on early traction from its newly approved ovarian cancer therapy and a string of upcoming clinical milestones.<a href="https://stocktwits.com/symbol/VSTM">VSTM stock</a> jumped over 2% in Wednesday’s regular session.<h2 class="st-heading-2">VSTM Q4 Review</h2>The company reported an adjusted loss of $0.48 per share for the fourth quarter (Q4), slightly wider than analysts’ $0.50-per-share loss estimate, while revenue came in at $17.5 million, topping the $16.84 million consensus estimate.Revenue in the quarter was driven by sales of Avmapki Fakzynja co-pack, a combination therapy approved by the U.S. Food and Drug Administration (FDA) in May 2025 for patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC).The therapy generated $17.5 million in net product revenue in Q4 and $30.9 million for the full year, marking the company’s first full year of commercial revenue from the drug following its accelerated approval.“2025 was a transformative year for us, highlighted by the landmark FDA approval of Avmapki Fakzynja co-pack,” CEO Dan Paterson said, adding that the treatment is seeing “positive response across the LGSOC community with gynecologic and medical oncologists.”Verastem ended 2025 with $205 million in cash, cash equivalents, and investments. The company said funds will support operations into the first half of 2027.<h2 class="st-heading-2">VS-7375 Cancer Drug Advances In Early Trials</h2>Investors also focused on updates related to VS-7375, Verastem’s oral KRAS G12D inhibitor being developed for solid tumors.The company said the therapy has cleared multiple dose levels in early studies with no dose-limiting toxicities, allowing dose escalation to continue to 1,200 mg once daily. A 600 mg daily dose in combination with Cetuximab, a form of cancer therapy, has also been cleared without safety concerns, with higher dose levels now being evaluated.Following feedback from the FDA, Verastem said it plans to pursue Phase 2 registration-directed studies for VS-7375 in several cancer indications, including second-line pancreatic ductal adenocarcinoma, second or third-line non-small cell lung cancer, and later-line colorectal cancer in combination with Cetuximab.<h2 class="st-heading-2">Verastem Flags Multiple Pipeline Catalysts</h2>Verastem outlined several upcoming milestones that could drive investor interest in the months ahead. The company expects to report early clinical data from the VS-7375-101 study in the first half of 2026 and select the recommended Phase 2 dose with Cetuximab, allowing it to begin a colorectal cancer combination expansion cohort later in the first half of 2026.Enrollment in combination dose-escalation cohorts is expected to be completed by mid-2026, while monotherapy expansion cohorts are projected to finish enrollment in the second half of 2026. The company also plans to select the recommended Phase 2 dose and begin pancreatic and lung cancer combination expansion cohorts in the second half of the year.Separately, Verastem said it plans to present updated data from the Ramp 201 trial of Avmapki Fakzynja at the Society of Gynecologic Oncology annual meeting in April, while longer-term development continues through the Ramp 301 Phase 3 trial, which is expected to report a topline primary endpoint readout in mid-2027.The company is also preparing an update on the Ramp 205 study, which evaluates the therapy in combination with chemotherapy for first-line metastatic pancreatic cancer, with results expected in the second quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for VSTM was ‘extremely bullish’ amid a 450% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/vstm_ss_png_aa5fb80917.webp" alt="vstm ss.png" width="962" height="136"><figcaption>VSTM sentiment and message volume as of March 4 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/CrozrX/message/646623324">said</a>, “Phenomenal safety with VS-7375 and as a bonus, all resolved quickly!!”<stembedurl>https://stocktwits.com/CrozrX/message/646623324</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Universaal/message/646621923">said</a> they “like what I heard this is going $7 plus tomorrow”<stembedurl>https://stocktwits.com/Universaal/message/646621923</stembedurl>VSTM stock has declined 25% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Verastem Oncology logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss?

The company flagged several catalysts ahead, including early VS-7375 data in the first half of the year, and Ramp 205 pancreatic cancer study results in Q2.

Equity

Verastem Q4 Earnings Call Highlights

Verastem (NASDAQ:VSTM) executives said the company's transition to a commercial-stage business accelerated in 2025 following FDA approval of AVMAPKI FAKZYNJA CO-PACK, the first treatment specifically...

Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates

Verastem (VSTM) delivered earnings and revenue surprises of -2.04% and +0.20%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Verastem (NASDAQ:VSTM) Issues Earnings Results

Verastem (NASDAQ:VSTM - Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, beating analysts...

Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the three...

Verastem (VSTM) Projected to Post Earnings on Wednesday

Verastem (NASDAQ:VSTM) will be releasing its Q4 2025 earnings after the market closes on Wednesday, March 4. (View Earnings Report at...

Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a...

What Makes Verastem (VSTM) a New Buy Stock

Verastem (VSTM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Verastem Touts 50%+ Sales Growth for LGSOC Launch, Teases RAMP 301 and KRAS G12D Catalysts

Verastem (NASDAQ:VSTM) executives highlighted commercial momentum for the company's newly launched ovarian cancer therapy and laid out near-term clinical catalysts across its RAS-pathway pipeline...

FY2025 EPS Estimates for Verastem Increased by HC Wainwright

Verastem, Inc. (NASDAQ:VSTM - Free Report) - Equities research analysts at HC Wainwright increased their FY2025 earnings estimates for Verastem in a note issued to investors on Thursday, February...

$VSTM Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.39 up 70.68% YoY
• Reported revenue of $17.54M
• Verastem expects a cash runway into the first half of 2027, fueled by existing cash and product revenue. The company aims to accelerate VS-7375 clinical development and report RAMP 301 trial topline data in mid-2027.

Stocktwits

Verastem Inc

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of -$0.39 up 70.68% YoY
• Reported revenue of $17.54M
• Verastem expects a cash runway into the first half of 2027, fueled by existing cash and product revenue. The company aims to accelerate VS-7375 clinical development and report RAMP 301 trial topline data in mid-2027.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

$VSTM Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.39 up 70.68% YoY
• Reported revenue of $17.54M
• Verastem Oncology expects its cash runway into the first half of 2027, supported by existing cash and product revenue. The company prioritizes driving AVMAPKI FAKZYNJA CO-PACK launch and accelerating VS-7375 clinical development.

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of -$0.39 up 70.68% YoY
• Reported revenue of $17.54M
• Verastem Oncology expects its cash runway into the first half of 2027, supported by existing cash and product revenue. The company prioritizes driving AVMAPKI FAKZYNJA CO-PACK launch and accelerating VS-7375 clinical development.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

VSTM
Verastem Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VSTM News

VSTMVerastem Inc